CLINICAL RESEARCH
Effect of terazosin hydrochloride in airways of patients with bronchial asthma
Submission date: 2016-07-15
Final revision date: 2016-08-01
Acceptance date: 2016-08-06
Publication date: 2016-09-08
Arch Med Sci Civil Dis 2016;1(1):81-86
KEYWORDS
TOPICS
ABSTRACT
Introduction: This study aimed to determine the potential effect of terazosin hydrochloride on bronchodilatation and compare it with the agonist effect of salbutamol in patients with asthma and bronchial hyperreactivity.
Material and methods: Twelve patients with the diagnosis of asthma and increased bronchial hyperreactivity were enrolled in an open label cohort study. We registered the functional pulmonary parameters by body plethysmography, including airway resistance, intrathoracic gas volume and specific resistance in each clinical subject. Terazosin hydrochloride was orally administered in the dosage of 1 mg and 2 mg tablets.
Results: The results of this study performed in patients with bronchial asthma and hyperreactivity showed that the blockade of specific α1-adrenergic receptors with terazosin hydrochloride (1 mg and 2 mg, oral tablets) did not change significantly (p > 0.1) bronchomotor tone of the tracheobronchial system compared with the group of patients treated with salbutamol (specific agonist of β2-adrenergic receptors). The arterial blood pressure decreased slightly, but not significantly, after use of 1 mg and 2 mg tablets of terazosin hydrochloride.
Conclusions: The results of the study show that the activity of specific α1-adrenoreceptors in tracheobronchial smooth muscle tone is not the primary mechanism for bronchorelaxation in patients with increased bronchial reactivity. The antagonism of α1-adrenoreceptors has a minor impact on the tracheobronchial tone compared with the agonist effect of β2-adrenergic drugs, which cause a significant decrease in specific resistance of airways.
Material and methods: Twelve patients with the diagnosis of asthma and increased bronchial hyperreactivity were enrolled in an open label cohort study. We registered the functional pulmonary parameters by body plethysmography, including airway resistance, intrathoracic gas volume and specific resistance in each clinical subject. Terazosin hydrochloride was orally administered in the dosage of 1 mg and 2 mg tablets.
Results: The results of this study performed in patients with bronchial asthma and hyperreactivity showed that the blockade of specific α1-adrenergic receptors with terazosin hydrochloride (1 mg and 2 mg, oral tablets) did not change significantly (p > 0.1) bronchomotor tone of the tracheobronchial system compared with the group of patients treated with salbutamol (specific agonist of β2-adrenergic receptors). The arterial blood pressure decreased slightly, but not significantly, after use of 1 mg and 2 mg tablets of terazosin hydrochloride.
Conclusions: The results of the study show that the activity of specific α1-adrenoreceptors in tracheobronchial smooth muscle tone is not the primary mechanism for bronchorelaxation in patients with increased bronchial reactivity. The antagonism of α1-adrenoreceptors has a minor impact on the tracheobronchial tone compared with the agonist effect of β2-adrenergic drugs, which cause a significant decrease in specific resistance of airways.
REFERENCES (23)
1.
Rudner LX, Berkowitz DE, Booth JV, et al. Subtype specific regulation of human vascular alpha1-adrenergic receptors by vessel bed and age. Circulation 1999; 100: 2336-43.
2.
Mathur SK, Sharma AK, Mathur R, et al. A short term comparative study of effects of alpha-adrenoreceptor blocker (Terazosin) and beta-adrenoreceptor blocker (Celiprolol) an respiratory parameters in mild-to-moderate hypertensive patients. Int J Sci Res 2014, 3: 266-9.
3.
Malerba M, Agabiti-Rosei M. Respiratory effects of antihypertensive agents acting on alpha adrenergic receptors. Recenti Prog Med 1991; 82: 682-5.
4.
Cazzola M, Page CP, Rogliani P, Matera MG. Beta2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013; 187: 690-6.
5.
Pera T, Penn RB. Bronchoprotection and bronchorelaxation in asthma: new targets, and new ways to target the old ones. Pharmacol Ther 2016; 164: 82-96.
6.
Zamel N, Faraco EZ, De Freitas FM. Effects of norepinephrine and isoprenaline on the airway resistance of patients with chronic bronchial obstruction. Thorax 1966; 21: 333-6.
7.
Dinh Xuan AT, Chaussain M, Regnard J, Lockhart A. Pretreatment with an inhaled alpha1-adrenergic agonist methoxamine, reduces exercise-induced asthma. Eur Respir J 1989; 2: 409-14.
8.
Sanchez I, Koster JD, Wolstein R, Chernick V. Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis. J Pediatr 1993; 122: 145-51.
9.
Van Mieghem W, Stevens E, Billiet L. Phentolamine therapy in severe chronic asthmatiform bronchitis. Respiration 1981; 42: 184-7.
10.
Shiner RJ, Mohlo MI. Comparison between alpha-adrenergic antagonist and a beta2-adrenergic agonist in bronchial asthma. Chest 1983; 83: 602-6.
11.
Campbell SC. Effects of alpha-adrenergic blockade with phentolamine on airway function in asthma. Ann Allergy 1982; 49: 135-8.
12.
Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059-68.
13.
Sica DA. Doxazosin and congestive heart failure. Congest Heart Fail 2002; 8: 178-84.
14.
Fusco F, Palmieri A, Ficarra V, et al. Alpha1-blockers improve benign prostatic obstruction in men with lower urinary tract smptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol 2016; 69: 1091-101.
15.
Torimoto K, Hirao Y, Matsuyoshi H, et al. Alpha1-adrenergic mechanism in diabetic urethral dysfunction in rats. J Urol 2005; 173: 1027-32.
16.
Biernacki W, Flenley DC. Doxazosin, a new alpha-1-antagonist drug, controls hypertension without causing airways obstruction in asthma and COPD. J Hum Hypertens 1989; 3: 419-25.
17.
Itskovitz HD. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings. Clin Ther 1994; 16: 490-504.
18.
Sirak TE, Jelic S, Le Jemtel TH. Therapeutic update: non-selective beta- and alpha- adrenergic blockade in patients with coexisting chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44: 497-502.
19.
Vincent J, Dachman W, Blaschke FT, Hoffman BB. Pharmacological tolerance to alpha1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Investig 1992; 90: 1763-8.
20.
Awan NA, Lee G, De Maria AN, Mason DT. Ambulatory prazosin treatment of chronic congestive heart failure development of late tolerance reversible by higher dosage and interrupted substitution therapy. Am Heart J 1981; 101: 541-7.
21.
Attanasi A, Consilvio NP, Rapino D, et al. Bronchial hyperresponsiveness to mannitol, airway inflammation and asthma control test in atopic asthmatic children. Arch Med Sci 2016; 12: 137-44.
22.
Thomson NC, Daniel EE, Hargreave FE. Role of smooth muscle alpha1-receptors in nonspecific bronchial responsiveness in asthma. Am Rev Respir Dis 1982; 126: 521-5.
23.
Chapman N, Chen CY, Fujita T, et al. Time to re-appraise the role of alpha-1 adrenoreceptor antagonists in the management of hypertension? J Hypertens 2010; 28: 1796-803.
| ISSN: | 2451-0637 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
